Table 2.
Effect of Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase (PD-ECGF/TP), Ovarian Cancer Cyst Fluids 1 and 2, and Furtulon on Microvessel Number in a Three-Dimensional Serum-Free Model of Angiogenesis
| Test substances | Microvessel number (% of control, mean ± SD) | |||
|---|---|---|---|---|
| Day 4 | Day 7 | Day 11 | Day 14 | |
| PD-ECGF/TP | 134.8 ± 15.2 | 121.6 ± 29.9 | 121.5 ± 26.4 | 136.9 ± 25.1 |
| Cyst fluid 1 | 188.4 ± 33.2 | 139.6 ± 36.8 | 155.0 ± 39.3 | 170.9 ± 18.4 |
| Cyst fluid 2 | 185.2 ± 35.7 | 150.9 ± 37.9 | 275.0 ± 60.1 | 240.5 ± 21.4 |
| Furtulon | 106.3 ± 28.5 | 80.1 ± 14.2 | 50.3 ± 12.8 | 36.0 ± 2.3 |
| Furtulon plus PD-ECGF/TP | 95.2 ± 25.3 | 32.6 ± 7.7 | 7.5* | 3.6* |
| Furtulon plus cyst fluid 1 | 114.3 ± 25.2 | 49.9 ± 15.5 | 20.0 ± 5.0 | 7.9* |
| Furtulon plus cyst fluid 2 | 169.3 ± 35.9 | 59.7 ± 7.7 | 25.0* | 9.5* |
There were 7 to 10 explants per experiment. The following concentrations were used: PD-ECGF/TP, 10 ng/ml; ovarian cancer cyst fluids, 2% v/v; Furtulon, 10 μmol/L. Number of control vessels used were as follows: 20 on day 4, 18 on day 7, 20 on day 11, and 21 on day 14; 28 explants (7 per day) were used.
* Data not normally distributed due to zero values for individual replicates.